Amyloid-β immunotherapy for Alzheimer's disease:: the end of the beginning

被引：362

作者：

Schenk, D ^{[1
]}

机构：

[1] Elan Pharmaceut, San Francisco, CA 94080 USA

来源：

NATURE REVIEWS NEUROSCIENCE | 2002年 / 3卷 / 10期

关键词：

D O I：

10.1038/nrn938

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

The agents that are available at present for the management of Alzheimer's disease treat only the symptoms of neurodegeneration and, at best, result in modest, short-term improvements in cognitive function. Immunotherapy represents one of the first tests of the amyloid hypothesis in the clinic, and is an evolving approach to the treatment of Alzheimer's disease that offers a genuine opportunity to modify disease progression. Although initial clinical trials of one approach met with some setbacks, active or passive immunization holds great potential for treating or even preventing Alzheimer's disease.

引用

页码：824 / 828

页数：6

共 23 条

[1]

Bacskai BJ, 2002, J NEUROSCI, V22, P7873

[2] Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].

Bard, F ;

Cannon, C ;

Barbour, R ;

Burke, RL ;

Games, D ;

Grajeda, H ;

Guido, T ;

Hu, K ;

Huang, JP ;

Johnson-Wood, K ;

Khan, K ;

Kholodenko, D ;

Lee, M ;

Lieberburg, I ;

Motter, R ;

Nguyen, M ;

Soriano, F ;

Vasquez, N ;

Weiss, K ;

Welch, B ;

Seubert, P ;

Schenk, D ;

Yednock, T .

NATURE MEDICINE, 2000, 6 (08) :916-919

[3] Familial Alzheimer's disease-linked presenilin 1 variants elevate A beta 1-42/1-40 ratio in vitro and in vivo [J].

Borchelt, DR ;

Thinakaran, G ;

Eckman, CB ;

Lee, MK ;

Davenport, F ;

Ratovitsky, T ;

Prada, CM ;

Kim, G ;

Seekins, S ;

Yager, D ;

Slunt, HH ;

Wang, R ;

Seeger, M ;

Levey, AI ;

Gandy, SE ;

Copeland, NG ;

Jenkins, NA ;

Price, DL ;

Younkin, SG .

NEURON, 1996, 17 (05) :1005-1013

[4] Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice [J].

Citron, M ;

Westaway, D ;

Xia, WM ;

Carlson, G ;

Diehl, T ;

Levesque, G ;

JohnsonWood, K ;

Lee, M ;

Seubert, P ;

Davis, A ;

Kholodenko, D ;

Motter, R ;

Sherrington, R ;

Perry, B ;

Yao, H ;

Strome, R ;

Lieberburg, I ;

Rommens, J ;

Kim, S ;

Schenk, D ;

Fraser, P ;

Hyslop, PS ;

Selkoe, DJ .

NATURE MEDICINE, 1997, 3 (01) :67-72

[5] MUTATION OF THE BETA-AMYLOID PRECURSOR PROTEIN IN FAMILIAL ALZHEIMERS-DISEASE INCREASES BETA-PROTEIN PRODUCTION [J].

CITRON, M ;

OLTERSDORF, T ;

HAASS, C ;

MCCONLOGUE, L ;

HUNG, AY ;

SEUBERT, P ;

VIGOPELFREY, C ;

LIEBERBURG, I ;

SELKOE, DJ .

NATURE, 1992, 360 (6405) :672-674

[6] Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease [J].

DeMattos, RB ;

Bales, KR ;

Cummins, DJ ;

Dodart, JC ;

Paul, SM ;

Holtzman, DM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8850-8855

[7] Brain to plasma amyloid-β efflux:: a measure of brain amyloid burden in a mouse model of Alzheimer's disease [J].

DeMattos, RB ;

Bales, KR ;

Cummins, DJ ;

Paul, SM ;

Holtzman, DM .

SCIENCE, 2002, 295 (5563) :2264-2267

[8] Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model [J].

Dodart, JC ;

Bales, KR ;

Gannon, KS ;

Greene, SJ ;

DeMattos, RB ;

Mathis, C ;

DeLong, CA ;

Wu, S ;

Wu, X ;

Holtzman, DM ;

Paul, SM .

NATURE NEUROSCIENCE, 2002, 5 (05) :452-457

[9] Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration [J].

Frenkel, D ;

Katz, O ;

Solomon, B .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (21) :11455-11459

[10] New insights into the genetics of Alzheimer's disease [J].

Hardy, J .

ANNALS OF MEDICINE, 1996, 28 (03) :255-258

← 1 2 3 →